EFSA's temporary acceptable daily intake and data gaps
In its 2018 re-evaluation EFSA set a temporary group ADI of 75mg/kg body weight per day covering both E407 and E407a together. It was made temporary specifically because of missing data: no molecular weight distribution profiles for individual E407a preparations, absent stability studies under the acidic or high-temperature conditions found in many permitted food uses, and limited characterisation of the test materials used in toxicology studies. EFSA requested this information within five years, meaning the safety case remains incomplete.
EFSA established a temporary group ADI of 75mg/kg body weight per day for carrageenan and processed eucheuma seaweed combined, flagging several missing datasets including molecular weight profiles and stability data under food-relevant conditions.
2018Regulatory reviewEFSA Panel on Food Additives and Nutrient Sources (ANS), EFSA Journal
High exposure in toddlers
EFSA's dietary modelling found that toddlers aged 12 to 35 months who consistently consume the same branded products (a 'brand-loyal' scenario) could reach estimated intakes of around 758mg/kg body weight per day, roughly ten times the temporary ADI. Even in average consumption scenarios toddlers were among the highest-exposed group. This does not mean harm has been demonstrated at those levels, but it does mean the safety headroom is not large for this age group.
Brand-loyal dietary modelling for toddlers produced exposure estimates of approximately 758mg/kg body weight per day, around ten times the temporary ADI set for the group.
2018Regulatory reviewEFSA Panel on Food Additives and Nutrient Sources (ANS), EFSA Journal
Gut inflammation and bowel disease uncertainty
Animal and cell studies have repeatedly shown that high doses of carrageenan can trigger intestinal inflammation. EFSA acknowledged 'inadequate data on the possible relevance of carrageenan exposure for existing inflammatory bowel diseases in humans' as a significant unresolved uncertainty. A 2023 scoping review in Critical Reviews in Toxicology identified plausible biological pathways by which food-grade carrageenan and E407a could adversely affect the gut lining and microbiome. The research is at hypothesis stage for humans; a causal link has not been established.
EFSA identified inadequate human data on whether carrageenan intake is relevant to existing inflammatory bowel diseases, listing it as a significant uncertainty requiring clarification.
2018Regulatory reviewEFSA Panel on Food Additives and Nutrient Sources (ANS), EFSA Journal
Animal models consistently show that high-dose carrageenan causes intestinal inflammation and altered gut barrier function; the relevance to normal dietary exposure in humans remains uncertain.
2002Lab + animalCohen S M and Ito N, Critical Reviews in Toxicology, 32(5):413-44
A scoping review identified hypotheses and some mechanistic evidence that E407/E407a may adversely affect the intestines via gut microbiome disruption and barrier permeability, while noting that definitive human evidence is lacking.
2023ObservationalCruickshanks et al., Critical Reviews in Toxicology
Carcinogenicity and genotoxicity: not a concern at food additive level
EFSA concluded that neither carrageenan nor E407a raised a concern for genotoxicity or carcinogenicity at the levels used as food additives. A critical distinction in the older literature is between food-grade carrageenan (high molecular weight, not absorbed from the gut) and 'degraded carrageenan' (poligeenan, produced by strong acid hydrolysis), which is not a food additive and is not the same substance. IARC first evaluated carrageenan in Volume 31 (1983); in Supplement 7 (1987) IARC formally classified food-grade carrageenan as Group 3 (not classifiable as to carcinogenicity in humans) and degraded carrageenan (poligeenan) as Group 2B (possibly carcinogenic to humans), based on evidence of colorectal cancer induction in rats given high doses of the degraded form. No re-evaluation has been published since.
EFSA found no concern with respect to genotoxicity or carcinogenicity for carrageenan and processed eucheuma seaweed at levels of use as food additives.
2018Regulatory reviewEFSA Panel on Food Additives and Nutrient Sources (ANS), EFSA Journal
IARC classified food-grade (native) carrageenan as Group 3 (not classifiable as to carcinogenicity in humans) and degraded carrageenan (poligeenan) as Group 2B (possibly carcinogenic to humans). The group designations were formalised in Supplement 7 (1987), building on the data evaluation in Volume 31 (1983). Degraded carrageenan is not permitted as a food additive.
1987RegulatoryIARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 31 (1983) and Supplement 7 (1987)
Not recommended in infant formula
EFSA endorsed the position that it is inadvisable to use carrageenan in infant formula from birth. This recommendation has been carried into EU legislation, which prohibits E407 and E407a in infant formula and follow-on formula. In the UK this restriction is maintained under assimilated law.
EFSA concluded that it remains inadvisable to use carrageenan (E407) or processed eucheuma seaweed (E407a) in infant formula from birth.
2018Regulatory reviewEFSA Panel on Food Additives and Nutrient Sources (ANS), EFSA Journal